| Literature DB >> 31524671 |
Hasan Ali Barman1, Serdar Kahyaoglu2, Eser Durmaz3, Adem Atici4, Kamil Gulsen5, Sevil Tugrul5, Hasan Burak Isleyen5, Mehmet Rifat Yildirim5, Baris Gungor6, Ertugrul Okuyan5, Irfan Sahin5.
Abstract
This study was performed to evaluate the relationship between the CHA2DS2-VASc score and no-reflow (NR) phenomena in patients with non-ST-segment elevation myocardial infarction (NSTEMI). A total number of 428 consecutive patients with NSTEMI were assessed for this study. Patients were divided into 2 groups, those with NR, NR(+) (n=84), and those without NR, NR(-) (n=307), according to their post-PCI, no-reflow status. The CHA2DS2-VASc score was significantly higher in the NR(+) group compared to the NR(-) (3.48 ± 1.19 vs 1.81 ± 0.82, P < 0.001). After a multivariate regression analysis, a higher CHA2DS2-VASc score (OR: 6.52, 95% CI: 3.51-12.14, P < 0.001), hs-Troponin (OR: 1.077, 95% CI: 1.056-1.099, P< 0.001) and TTG (OR: 1.563, 95% CI: 1.134-2.154, P=0.006) were independent predictors of NR. CHA2DS2-VASc score is associated with higher risk of no-reflow in patients with NSTEMI undergoing PCI.Entities:
Mesh：
Substances：
Year: 2020 PMID： 31524671 DOI： 10.1097/MCA.0000000000000781
Source DB: PubMed Journal: Coron Artery Dis ISSN： 0954-6928 Impact factor: 1.439